Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. on March 23, 2022, covering events occurring on March 23, 2022, and an agreement effective March 25, 2022. The filing primarily addresses the entry into a material definitive loan agreement and changes to the Board of Directors.
Key Financial Metrics and Debt
The filing details a new credit facility rather than historical operating results. Key financial terms include:
- Total Facility Size: Up to $150.0 million in term loans.
- Initial Draw: $25.0 million received on the effective date.
- Remaining Availability: $125.0 million subject to specific milestones or lender discretion.
- Interest Rate: Floating rate equal to the greater of the one-month CME Secured Overnight Financing Rate or 0.13%, plus 7.37%.
- Maturity Date: March 1, 2027.
- Final Payment: 5.0% of the original principal amount of drawn loans.
- Facility Fee: 0.5% of the principal amount.
- Covenants: The agreement contains no financial covenants.
The filing references a press release regarding financial results for the fourth quarter and full year ended December 31, 2021, but does not provide specific revenue, profit, or cash flow figures within this text.
Material Changes and Milestones
The loan agreement includes four additional tranches contingent on specific milestones:
- Term B Loan ($15.0 million): Triggered by receipt of a $35.0 million regulatory milestone payment from Secura Bio regarding COPIKTRA approval for PTCL, or receipt of at least $50.0 million in unrestricted equity proceeds. Must be drawn by March 31, 2023.
- Term C Loan ($25.0 million): Triggered by FDA accelerated or full approval of VS-6766 for low-grade serous ovarian cancer. Must be drawn by March 31, 2024.
- Term D Loan ($35.0 million): Triggered by achieving at least $50.0 million in gross product revenue on a trailing six-month basis. Must be drawn by March 31, 2025.
- Term E Loan ($50.0 million): Subject to the sole discretion of the lenders.
Management Commentary, Risks, and Governance
Use of Proceeds: Funds are designated for future working capital needs and general corporate purposes.
Collateral: The Company granted a security interest in all personal property (excluding intellectual property itself, but including rights to payments/proceeds) and a negative pledge on intellectual property.
Events of Default: Includes payment defaults, breach of representations, insolvency, and material adverse changes. Default triggers an interest rate increase of 5.00% above the applicable rate and potential acceleration of obligations.
Board Changes: Tim Barberich retired from the Board effective March 31, 2022. Lesley Solomon was reclassified from Class III to Class II Director to equalize board class sizes, effective March 31, 2022, with no change to her compensation or committee assignments.
Investor Verification Checklist
- Verify the status of the $35.0 million regulatory milestone payment from Secura Bio regarding COPIKTRA to assess the likelihood of drawing the Term B Loan.
- Confirm the current development status and FDA review timeline for VS-6766 to evaluate the Term C Loan milestone.
- Review the full text of the Loan Agreement (Exhibit 10.1) for detailed definitions of "Material Adverse Change" and specific prepayment fee calculations.
- Examine the referenced press release (Exhibit 99.2) for actual Q4 and full-year 2021 financial results, as this 8-K does not contain specific revenue or cash flow numbers.
- Monitor the Company's cash burn rate relative to the initial $25.0 million draw to determine the urgency of meeting future milestones.